TCT 2022 | Pulmonary Artery Denervation in Primary Pulmonary Hypertension

Primary Pulmonary Hypertension is behind multiple hospitalizations and pulmonary transplants. Even though its treatment has been advanced, many patients will not respond well. 

TCT 2022

The PADN-CFDA randomized 128 patients, 63 received pulmonary denervation (PADN) and 65 went to the control group.

Primary end point was 6-minute walk distance test at 6 months. 

The populations were similar, mean age was 44 and 90% were women. 

Primary end point resulted in favor of PADN, in addition to reducing NT pro BNP and pulmonary vascular resistance. 

The 6-month Eco-Doppler showed improved right ventricular function and improved tricuspid regurgitation, and the right catheterization procedure showed reduced pulmonary artery hypertension and increased volume per minute.  

Read also: TCT 2022 | RADIANCE II Pivotal Trial.

The authors have concluded that PADN is safe, improves 6-minute walk distance and also brings about improved eco-Doppler and pulmonary hypertension, reduced pulmonary vascular resistance and decreased NT pro BNP.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of

Original Title: Pulmonary Artery Denervation for Pulmonary Arterial Hypertension: A Sham-Controlled Randomised Trial

Presenter: ShaoLiang Ch.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology